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Several  evidences  support  the  concept  that  cancer  development  and  progression  are  not  entirely  cancer
cell-autonomous  processes,  but  may  be  inﬂuenced,  and  possibly  driven,  by cross-talk  between  cancer
cells  and the  surrounding  microenvironment  in  which,  besides  immune  cells, stromal  cells  and  extracel-
lular  matrix  (ECM)  play  a major  role in  regulating  distinct  biologic  processes.  Stroma  and  ECM-relatedeywords:
reast cancer
umor microenvironment
xtracellular matrix
umor stroma component
signatures  proved  to  inﬂuence  breast  cancer  progression,  and  to  contribute  to  the  identiﬁcation  of  tumor
phenotypes  resistant  to cytotoxic  and  hormonal  treatments.  The  possible  clinical  implications  of  the
interplay  between  tumor  cells  and  the microenvironment,  with special  reference  to ECM  remodelling,
will  be discussed  in  this  review.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).CM-related signatures
. Introduction
Although cancer has been considered as a progression of genetic
utations in an aberrant tissue mass, tumors are increasingly
iewed as tissues functionally interconnected with the surround-
ng microenvironment [1]. Recent genome sequencing and single
ell-based analyses have revealed substantial genetic heterogene-
ty within tumors, with subclones that differ in driver mutations.
n a breast carcinoma model [2], growth was sustained by a minor
ell subpopulation that facilitated the proliferation of all tumor
ells. Interestingly, this subpopulation stimulated tumor growth
hrough microenvironmental changes related to re-organization
f the collagen pattern and induction of intratumoral vasculariza-
ion, suggesting that progression of a tumor relies on its ability to
vercome microenvironment constraints.
Abbreviations: ER, estrogen receptor; IDC, invasive ductal carcinoma; DCIS,
uctal carcinoma in situ; FEC, 5-ﬂuorouracil+doxorubicin+cyclophosphamide; NKI,
etherland Cancer Institute; ECM, extracellular matrix; SFT, solitary ﬁbrous tumors;
TF, desmoid-type ﬁbromatosis.
∗ Corresponding author. Tel.: +39 02 2390 2700; fax: +39 02 2390 2764.
∗∗ Corresponding author. Tel.: +39 02 2390 3013; fax: +39 02 2390 2764.
E-mail addresses: marta.giussani@istitutotumori.mi.it
M.  Giussani), giuseppe.merlino@istitutotumori.mi.it (G. Merlino),
era.cappelletti@istitutotumori.mi.it (V. Cappelletti),
lda.tagliabue@istitutotumori.mi.it (E. Tagliabue),
ariagrazia.daidone@istitutotumori.mi.it (M.G. Daidone).
ttp://dx.doi.org/10.1016/j.semcancer.2015.09.012
044-579X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).The tumor microenvironment consists of an insoluble extracel-
lular matrix (ECM), a stroma composed of ﬁbroblasts, adipocytes,
endothelial and resident immune cells, and a multitude of growth
factors and cytokines. The ECM itself is composed by a complex
mixture of components, including proteins, glycoproteins, proteo-
glycans and polysaccharides [3,4]. In addition to elucidating the
role of single ECM components in development and homeostasis
of normal breast, many studies have revealed abnormal changes in
the amount and organization of such molecules during breast car-
cinoma development. These changes lead to altered biochemical
and physical properties of tumor-associated ECM that contribute
to tumor progression and resistance to therapy. Moreover, dereg-
ulation of ECM architecture impacts on tumor surrounding stroma
cells, including endothelial, immune and other stromal cells which
may come to favor tumor development. Although many single
ECM components, reviewed in [5], have been identiﬁed as rel-
evant markers in breast carcinoma progression, evaluation and
targeting of a single molecule appears to have limited usefulness
in predicting disease outcome or improving therapeutic beneﬁt. A
possible explanation might rest in the large number of ECM com-
ponents, which, even if likely redundant, collectively contribute to
distinctive physical, biochemical and biomechanical properties of
the tumor microenvironment.To address the complexity of the tumor ECM and elucidate the
stromal properties relevant for breast carcinoma progression and
response to therapy, cancer research in the last decade has shifted
to gene expression studies focused on the tumor stromal compo-
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ent. In this context, different experimental approaches have been
pplied, including proﬁling of: (a) stromal cells isolated from car-
inomas or modiﬁed by cultured conditions; (b) soft tissue tumors
s surrogates for different stromal responses; (c) laser-captured
umor microenvironment or whole tumor samples followed by
nalysis of a gene set restricted to connective tissue-related genes.
he ﬁrst gene expression portrait of the breast cancer microen-
ironment came from a study [6] in which different stromal cell
ypes composing normal and neoplastic tissues were proﬁled using
erial analysis of gene expression upon separation by magnetic
eads armed against cell type-speciﬁc surface markers. Signiﬁcant
hanges in gene expression proﬁle were detected in all cell types
uring tumor progression, indicating that the microenvironment
ctively participates in cancer growth and invasion. Focusing on
yoepithelial cells as constituents relevant in controlling breast
ancer cell growth, the authors detected upregulated expression
f several proteases (cathepsin F, K and L, MMP2  and PRSS19),
rotease inhibitors (thrombospondin2, SERPING1, cytostatin C and
IMP3) and different collagens (COL1A1, COL3A1, COL6A1) in DCIS
yoepithelial cells [6] implying ECM remodeling during cancer
evelopment. These results were later conﬁrmed through the gene
xpression portrait of ﬁbroblasts derived from invasive and benign
reast diseases [7]. While analysis of gene expression proﬁles of
tromal tissue isolated using laser capture microdissection (LCMD)
howed no signiﬁcant differences between adjacent tumor and
eduction mammoplasty-derived stroma [8], genes involved in
CM-receptor interaction and focal adhesion were signiﬁcantly
p-modulated in tumor versus normal cells microdissected from
astectomy specimens of invasive ductal or lobular carcinomas
9]. Taking advantage of LCMD, gene expression proﬁles of patient-
atched normal stroma and tumor-associated stroma specimens
howed that the highest regulated genes in the tumor-associated
troma were those encoding ECM constituents and matrix metal-
oproteinases, including COL10A1, COL11A1, ﬁbronectin, collagen
riple helix repeat containing 1, COL12A1, COL8A1, MMP11, and
MP2  [10]. Thus, whereas early changes involved in cancer initi-
tion per se do not appear to derive from the microenvironment,
he cross-talk between tumor and stromal cells mediated though
he ECM is one of the ﬁrst events upon mammary cell transfor-
ation. As such, there is continuing scientiﬁc interest in the role
f cross-talk in neoplastic progression as well as in the promise
f ECM features as biomarkers able to predict risk of progres-
ion and treatment beneﬁt in breast carcinoma patients. Moreover,
ecent ﬁndings on the role of speciﬁc microRNAs regulating a
etwork of genes involved in ECM changes by tumor microen-
ironment or directly targeting ECM molecules mRNAs [11,12]
pen new perspectives for investigating whether any of such
troma/ECM variations are associated to release/modulation of sig-
aling molecules relevant for tumor progression which can be
asily detected in body ﬂuids for a relatively non-invasive early
iagnosis/risk assessment.
Here, we provide an overview of “microenviromental signa-
ures” proved to be relevant as markers for progression and
reatment of breast cancers. Since abnormal characteristics of
reast carcinoma ECM induce changes in tumor tissue architecture
nd rigidity, we  also discuss the role of stromal stiffness on tumor
ehavior.
. The role of ECM in the transition from ductal carcinoma
n situ to invasive breast cancerBefore the introduction of mammary screening, ductal carci-
oma in situ (DCIS) represented only 2–5% of symptomatic breast
ancers while, nowadays, it accounts for more than 20% of newly
iagnosed symptomatic cases and up to half of screen-detectedcer Biology 35 (2015) 3–10
breast cancer, but uncertainties still remain on its biological
behavior and the appropriate clinical management [13–15]. Thus,
the identiﬁcation of biomolecular markers associated to the risk
of in situ recurrence rather than of invasive cancer to complement
standard clinical and pathological factors represents an area of
intense research [16,17] for the possibility to provide patients with
a more appropriate use of local and systemic treatments.
At present, the progression of DCIS to invasive breast cancer may
be explained by mainly two  distinct mechanisms, as the results of
the accumulation of additional genetic aberrations and inherited
transcriptome alterations consequent to methylation modiﬁca-
tions or, alternatively, as a genetic-independent process. Many
studies focused on the molecular and genetic alterations in neoplas-
tic cells, but evidence is also emerging on the fact that the transition
from DCIS to invasive ductal carcinoma (IDC) is strongly depen-
dent upon alterations in the microenvironment with a particular
reference to the role of myoepithelial cells and stromal-epithelial
interactions.
Initial studies which focused on epithelial cells only, barely
found any gene expression differences among distinct stages of
progression [10,16], especially when the comparison was done
between in situ and invasive tumors of the same grade. Indeed at
the epithelial cell level, the more dramatic changes were reported
in the transition from normal epithelium to DCIS, with minor
changes between atypical ductal hyperplasia, DCIS and IDC. With
an increasing awareness on the role of the microenvironment in
tumor biology [18], studies were undertaken to molecularly dissect
the contribution of single microenvironmental components, and
the ﬁrst systemic study [6] on pure stromal cell subpopulations,
isolated from few samples of DCISs, IDCs and normal mammary
glands, demonstrated alterations in all the microenvironment com-
ponents across the progression to in situ and invasive growth, with
major changes occurring in the myoﬁbroblasts and myoepithelial
cells. Such alterations involved increased secretion of chemokines
(e.g., CXCL14, CXCL12), which stimulate in a paracrine fashion pro-
liferation, invasion and migration of tumor cells.
The transition from DCIS to IDC was also studied integrating
genomic alterations with transcriptomic proﬁles and again no sim-
ilarities could be observed also at the genomic level [19] suggesting
that these changes are shared between DCIS and IDC. Some caution
should however be used in the interpretation of data since in the
absence of a common mechanism accounting for DCIS progression,
individual tumor alterations could represent confounding factors
in patient-matched studies of DCIS/IDC as already observed when
the analysis was  done at single cell level [20,21].
On the front of the non-genomic hypothesis of the transition
from DCIS to IDC, Ma  et al. [10] performed the molecular charac-
terization of 14 patient-matched normal and tumor breast frozen
samples in which gene expression proﬁles were analyzed in LCMD-
isolated cells from normal breast epithelium, DCIS, IDC, normal
stroma compartment, DCIS- and IDC-associated stroma. The pro-
gression from in situ to invasive growth proved to be associated to
an extensive change in gene expression mainly in tumor-associated
stroma, with an up-regulation of matrix metalloproteinases genes
(MMP11, MMP2, MMP14 and MMP13) associated with invasion
and with ECM remodeling. Conversely, only three typical stromal
genes (POSTN, SPARC, SPARCL1) were up-modulated in the tumor
epithelium of IDC compared to DCIS.
Later studies addressed the issue of DCIS progression in a
similar way, comparing synchronous DCIS and IDC lesions, with
some differences in study design (not necessarily patient-matched)
and technical approaches (manually performed microdissection
on FFPE samples at a distance up to 3 mm  from the tumor
lesion). At difference to the previous studies, Vargas et al. [22]
observed major changes only in genes related to ECM remodeling
in the epithelial compartment, including an increased expression
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f COL11A1, COL5A2 and MMP13 in IDC samples. Altogether, these
esults highlight the level of complexity in investigating tumor-
icroenvironment interactions, in terms of importance of the
elative proximity of stromal and epithelial tumor cell compart-
ents, and of stromal contamination that could act as a confounder
n evaluating the modulation of ECM genes in the epithelial com-
artment. Finally, it is also well known that tumor cells, and not
nly ﬁbroblasts, produce ECM components and enzymes involved
n its remodeling. However, independently of the speciﬁc cellu-
ar types expressing ECM structural components or remodeling
nzymes, the transition to invasive disease appears convincingly
ssociated with ECM modiﬁcations, in keeping with data reported
y Lee et al. [23] who deﬁned gene signatures able to classify DCIS
nd IDC, enriched by genes involved in ECM synthesis, organiza-
ion and response to wounding. In a subgroup of patients, separate
pithelial and stromal gene expression data were also available,
uggesting that ECM-related ontologies signiﬁcantly enriched in
DC compared to DCIS were restricted to epithelial cells [23].
tromal genes supported instead a restricted angiogenesis and
esponse to glucocorticoids in invasive tumors.
Other suggestions on the role of microenvironment and ECM
erive from epidemiological observations regarding the postpar-
um increase in aggressive breast tumors linked to mammary gland
nvolution [24]. The stromal compartment of the mammary gland
hanges during women life-span, in particular mammary gland
nvolution occurring post-pregnancy and post-weaning (or at the
nset of the menopause) is associated with an increased incidence
f tumors [25]. During such an involution, the microenvironment
resents features common to inﬂammation and wound-healing,
nd for a long time epidemiologist have noticed that breast tumors
iagnosed post-pregnancy were characterized by a grim progno-
is not understandable simply on the basis of young age and/or
ise in hormone levels. In such a condition, the massive remodeling
f the ECM favors the progression of pre-invasive lesions [26] as
emonstrated in animal models where MCF10ADCIS human cells,
noculated into a mammary involuting environment, formed larger
umors characterized by abundant production of ﬁbrillary collagen
nd by an invasive behavior. Those cells frequently spread through
he mammary stroma and circulating tumor cells were identiﬁed
n peripheral blood in a very short time. Fibrillary collagene and
ctivation of COX-2 were instrumental for the acquisition of the
nvasive phenotype: collagen ﬁbers in the involuting gland were
adially aligned to ducts and the increased deposition of ﬁbrillary
ollagen during involution increased COX-2 expression, which was
equired for cell migration. These data further underline the role
f ECM in tumor progression and should indicate the rational of
dministering NSAIDs (able to block production and radial orga-
ization of ﬁbrillar collagen) to women at high-risk for local and
nvasive recurrence, [26].
Additional indications on the role of ECM-remodeling under
peciﬁc conditions in promoting tumor progression derive from
tudies on the gene coding for LOXL2, which promotes tissue inva-
ion by regulating the TIMP1 and MMP9  activity, whose expression
s co-regulated during mammary involution [27].
A long-time known barrier to the transition from in situ to inva-
ive growth is given by the presence of myoepithelial cells which
ot only constitute a physical fence, but have a molecular active role
n regulating ECM remodeling since secrete both ECM components
nd protease inhibitors (e.g., maspin) that prevent the conversion
o invasive phenotype [28]. DCIS animal models support such an
ypothesis suggesting that progression towards IDC is not due to
ntrinsic or eventually acquired properties of epithelial cells, but
ather determined by the complex interplay among all cell compo-
ents of the microenvironment, where stromal cells promote, and
yoepithelial cells inhibit DCIS to IDC transition [29].cer Biology 35 (2015) 3–10 5
Despite the fact that data are being accumulated on the possi-
ble effectors of DCIS-IDC transition and of ECM involvement in this
process, few translational studies so far published provided clini-
cally validated biomarkers/signatures to solve the clinical dilemma
of DCIS treatment. It has recently been shown that the expression
of HER2 [30] and of COX2 can predict DCIS recurrence and that, in
a clinical trial on women  with ER+ pure DCIS, treatment with the
COX-2 inhibitor colecoxib in addition to aromatase inhibitors was
biologically effective in reducing Ki67 and Cox-2 expression [31].
Future studies directly comparing validated biomarkers for speciﬁc
stromal cells activation and ECM remodeling and possibly taking
into account mammary density [32] would probably provide hints
for a more personalized therapy of patients with in situ disease at
risk of progression
3. ECM molecular signatures and disease recurrence
Evidence of molecular changes in the ECM accompanying breast
cancer progression has led to challenge as predictors of clini-
cal outcome stroma/ECM-related signatures, developed in pilot
studies on clinical samples or in preclinical studies in which
microenvironment cells were isolated and proﬁled or manipulated
in vitro to simulate a speciﬁc process. Nine translational stud-
ies were addressed to investigate whether ECM signatures might
be associated to clinical progression in stage I-III breast cancers
and/or to validate such ﬁndings on independent datasets even tak-
ing advantage of publicly available datasets (Table 1). Consistent
with the theory that the molecular program of tumor-associated
ﬁbroblasts dictates breast cancer aggressiveness, the transcrip-
tional response of normal ﬁbroblasts to serum [33] showed that
both distant metastasis-free and overall survival were signiﬁ-
cantly decreased in patients with tumors overexpressing genes
signiﬁcantly up-modulated in ﬁbroblasts by serum stimulation
[34]. Moreover, the ﬁbroblast-activated signature stratiﬁed breast
carcinomas according to risk of relapse regardless of previously
established biomolecular markers such as molecular subtypes and
70-gene prognosis signature in the independent dataset of 295
early breast carcinomas of the Netherlands Cancer Institute (NKI)
[35]. In addition to cell cycle genes, the genomic response of ﬁbrob-
lasts to serum includes ECM remodeling molecules (e.g., LOXL2,
PLOD2 and PLAUR), further suggesting that the composition and
architecture of insoluble stroma can serve as a biomarker for breast
cancer progression. However, it remains unclear why the same
microenvironment is not present in every tumor, and further inves-
tigations are needed to deﬁne whether and how intrinsic tumor or
host characteristics may  account for that observation.
The NKI dataset was  also challenged in the study by West et al.
[36] by signatures developed from a set of 786 genes with an
expression pattern that distinguishes soft tissue tumors [solitary
ﬁbrous tumors (SFT) and desmoid-type ﬁbromatosis (DTF] mirror-
ing different activation states of ﬁbroblastic cells. Two main gene
groups were apparent, one composed almost entirely of DTF genes
such as collagens involved in ﬁbrosis (e.g., COL1A1 and COL3A1),
and metalloproteinases including ADAMs and MMPs, and the sec-
ond group comprising two further clusters characterized by high or
low expression of SFT genes (e.g., COL4A5 and COL17A1) involved
in basal membrane formation. The two  signatures had signiﬁcantly
different behavior, with better clinical outcome in patients with
DTF-like breast cancer. These ﬁndings revealed distinct patterns
of stroma reaction, and also showed for the ﬁrst time that the
ECM molecular milieu correlates with differences in the biology
of tumors and consequently in clinical outcome. Support for the
robustness of the DTF expression signature for breast cancer prog-
nosis derives from the analysis of DTF-associated genes in four
independent breast cancer datasets [37]. The DTF signature has also
6
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Table 1
ECM signatures and clinical outcome of breast cancer patients.
Author
(reference)
Discovery Test settings Outcomes
Source of DE
genes/Platform for
expression analysis
Investigated
specimens/datasets
No. of
cases
Tumor
stage
Median
follow-up
(years)
Treatment Predictive
signature (no. of
genes)
Selected ECM-related
candidate genes*
Relation with
Chang
[33,34]
50 ﬁbroblast
cultures isolated
from 10 different
anatomical
sites/cDNA
Frozen primary
tumors
Public NKI dataset
[35]
58
295
III
I-II
6.5
7.8
Systemic
treatments
Surgery ± systemic
treatments
Distant metastasis & death by
uni/multivariable analyses, with a
worse prognosis for patients with
tumors enriched for serum
response program (=wound-like
phenotype) ﬁbromatosis.
West  [36]
Beck [37]
Tumors with
ﬁbroblastic
features/cDNA
Frozen primary
tumors
Publicly available
datasets[33]
295
561
I-II 7.8 Surgery ± systemic
treatments
2 ﬁbroblast-related
(483)
COL1A1
COL5A1, COL3A1
COL6A1 COL18A1
FBN1, TPM1
ADAM12, ADAM19
MMP1, MMP11
MMP19
MMP23b, COL4A5
COL17A1, MYL9, etc.
Distant metastasis & death by
uni/multivariable analyses, with a
better prognosis for patients with
tumors enriched for desmoid-type
ﬁbromatosis genes.
Finak  [8] LCMD-IDC
stroma/Agilent
Frozen primary
tumors
53 I-II 3.6 Surgery stroma-derived-
prognostic
predictor [26]
CXCL14
MMP1, MMP12
ITGBL1, SPP1
Relapse, validated by
uni/multi-variable analyses in
publicly available datasets [35,39].
Bergamaschi
[40]
Triulzi [41]
Tumor
tissues/Agilent
Frozen primary
tumors
Nowegian dataset
Publicly available
datasets [39,42]
28
114
192
I-II
I-II
I
Not speciﬁed
Not speciﬁed
5
Surgery ± systemic
treatments
Surgery ± systemic
treatments
Surgery
ECM-related genes
initially derived
from the literature
(282), and then
extended to 738
[39]
Structural ECM proteins
(encoded by ECM-3 genes and
including COL1A1 and COL5A2)
MMP2, ADAM12, ADAMTS2
ADAMTS5
CTSK, MMP11
MMP14, TIMP3
SERPINF1, SERPINH1
CDH11, SGCD, CNTN1, ITGB5
ITGBL1, MARCO, PUNC, SPARC
LAMA4
Distant metastasis & death, with a
prognosis better for patients with
ECM-4 and worse for those with
ECM-1 tumors
Worse prognosis for patients with
undifferentiated ECM-3 tumors, in
uni/multivariable analyses
Planche  [44] LCMD-IDC breast
stroma/Affymetrix
Public NKI dataset
[35]
295 I-II 7.8 Surgery ± systemic
treatments
Stromal signature
[36]
COL10A1
COL11A1, FN1, COMP, CADM1,
P4HA3, MMP11, MFAP2
Distant metastasis & death by
univariate analysis
Jansen  [53] Tumor tissue/cDNA Frozen ER+
primary tumors
112 IV 8 from
primary
surgery; 4.5
from start of
systemic
therapy
Tamoxifen
(1st line)
44-gene signature
(from the initial set
of 81 genes)
TIMP3,  FN1, LOX, COL1A1
SPARC,  TNC
Disease progression and resistance
to anti-estrogen therapy by
ECM-related genes
Helleman
[43]
Tumor
tissue/qRT-PCR
Frozen primary
tumors
1286
680
139
240
I-IV
I
II,ER+
IV,ER+
8.5 Miscellanea
surgery
Tamoxifen
Tamoxifen (1st
line)
5-gene signature
(from [53])
TIMP3, FN1, LOX, COL1A1,
SPARC,  TNC
Distant metastasis occurrence in
stage I associated with TIMP3, FN1,
LOX, SPARC expression levels
Resistance to anti-estrogen
therapy by TNC expression levels
Farmer  [56] Mixture of tumor
and stromal
cells/affymetrix
Frozen ER-primary
tumors
Public NKI dataset
[35]
63
295
II-III
I-II
Not speciﬁed
7.8
FEC (neo-adjuvant)
Surgery ± systemic
treatments
Stromal signature
[50]
Metagene including DCN,
COL1A2, COL10A1, COL3A1,
COL6A3, COL6A1, COL10A1,
MMP2, MMP11, MMP14,
SPARC,  LOXL1, FBLN1,
ADAM12, ECM2
Resistance to pre-operative FEC
chemotherapy associated with
high expression of the stroma
metagene
No association with clinical
outcome for patients not receiving
systemic therapy
* In bold, genes present in >1 signature, with a consistent association with the different clinical end-points.
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een described recently as a feature in other types of carcinomas
ovarian, colon and lung) [38], suggesting that up-modulation of
enes encoding ECM components is a common stromal response
o cancer development.
An additional stroma-derived signature, which has been devel-
ped by comparing the gene expression proﬁle of LCMD-tumor and
atched normal stroma from 53 primary IDCs, proved to be asso-
iated with relapse [8], and these results have been validated in
xternal independent datasets [35,39].
The ﬁndings that primary breast carcinomas can be classiﬁed
ased on ECM composition and that this classiﬁcation is rele-
ant for disease progression were conﬁrmed by our analysis of
78 genes encoding ECM molecules in primary breast carcinoma
amples proﬁled on an Agilent platform, wherein tumors were
ivided into four main groups (ECM1–4) that were signiﬁcantly
ndependent of intrinsic characteristics of neoplastic cells [40].
sing 4 different clustering algorithms to test the robustness of
his breast carcinoma classiﬁcation based on the expression pro-
le of ECM-related genes in 6 additional independent datasets of
43 invasive breast tumors proﬁled by different platforms, ECM3
umors were recognized as an independent subset including about
0% of breast carcinomas. ECM3-tumors identiﬁed across different
atasets consistently showed overexpression of 58 genes, including
3 encoding structural ECM proteins (e.g., different collagen chains,
bronectin, laminin, SPARC) coordinately overexpressed by both
tromal and breast cancer cells [41]. Multivariate analysis of two
oined datasets of node-negative, untreated primary breast carci-
oma patients [39,42] evidenced a signiﬁcant interaction between
CM3 and tumor differentiation status (genomic grade) and indi-
ated that ECM3 was signiﬁcantly associated with high risk of
elapse in patients with undifferentiated (grade III) tumors, inde-
endent of intrinsic molecular subtypes. These ﬁndings indicate the
igniﬁcance of interaction between tumor and ECM features in con-
rolling tumor progression and support not only the importance of
ross-talk between transformed cells and the microenvironment in
onditioning breast carcinoma evolution, but also the observation
hat the predictive value of the ECM depends on tumor cell-speciﬁc
roperties.
Consistent with these ﬁndings, an ECM gene cluster including
OL1A1, TIMP3, FN1, LOX, TNC and SPARC was shown to be relevant
or tumor prognosis as evaluated by quantitative real-time PCR in
286 primary breast carcinomas [43]. Speciﬁcally, TIMP3, FN1, LOX
nd SPARC were associated with metastasis-free survival in lymph
ode-negative patients who received no adjuvant therapy.
Genes encoding ECM components (e.g., COL11A1, COMP and FN)
ere signiﬁcantly up-modulated in tumor versus normal stroma
n a transcriptome analysis of LCMD-stromal cells derived from
uman invasive breast carcinomas [44]. Interestingly, hierarchi-
al clustering of a publicly available early-stage breast carcinoma
ataset [35] based only on the expression proﬁle of detected
tromal genes identiﬁed two groups of patients that differed sig-
iﬁcantly in overall survival.
With respect to ECM molecular modules associated with breast
ancer outcome, SPARC (secreted protein acidic and rich in cys-
eine) was shared by different signatures due to its relevance in
egulating ECM via interaction with different components as col-
agen, laminin, VEGF, PDGF [45–47], affecting tumor progression
ia regulation of integrin-linked kinases [48] and acting in the
mmune response and immunosurveillance against tumors [49]. A
ooled analysis of two publicly available datasets [35,50] to evalu-
te SPARC expression according to clinical outcome in early breast
ancer [51] showed that this matricellular protein as well as a
etagene including genes highly correlated with SPARC was sig-
iﬁcantly associated with poor prognosis in patients with basal and
ER2-positive breast tumors. Moreover, in neoadjuvantly treated
atients with HER-positive tumors, SPARC signature was  associ-cer Biology 35 (2015) 3–10 7
ated with resistance to chemotherapy, supporting the relevance
of the ECM structural framework in determining patient outcome.
Overall, the interaction between tumor and ECM features in tumor
progression, as abundantly described in preclinical models, appears
to be a key force affecting breast cancer evolution. The develop-
ment of new therapeutic interventions targeting this tumor niche
awaits further studies to deﬁne how biochemical and biophysical
properties of ECM components differ according to ECM molecu-
lar signature and whether the signal from the matrix to the cells
within depends primarily on ECM features or whether the tumor
cell differentiation status contributes.
4. ECM molecular signature and response to systemic
treatments
Tumor microenvironment can contribute to the occurrence of
tumor resistance to chemical and physical agents through differ-
ent mechanisms, which include (a) the presence of dense ECM or
limited blood ﬂow that may  limit drug availability to tumor cells;
(b) interactions of tumor cells with ECM constituents that may
activate survival pathways allowing the acquirement of resistance
through genetic changes; (c) secretion of pro-survival factors (e.g.,
growth factors, cytokines) by stromal cells [52]. Such ﬁndings are
supported even by translational studies within clinical trials, where
stroma- and ECM-derived signatures proved to be associated with
resistance to cytotoxic and anti-estrogen agents (Table 1).
Studies from the Erasmus Medical Center demonstrated the
association of the ECM gene cluster including COL1A1, TIMP3, FN1,
LOX, TNC and SPARC with tamoxifen resistance in patients with
metastatic breast cancer [53], and conﬁrmed in a successive study
also including adjuvant settings the involvement of TNC with anti-
estrogen resistance. The predictive relevance of TNC, which is a
target of microRNA-355 [54], could be explained by two mecha-
nisms: (1) high TNC expression may  be indicative of a defective
estrogen pathway in ER+ breast cancers; (2) TNC interacts with
integrins, which are targets of microRNA-31 [55] and could activate
growth factor signaling or act directly as a growth stimulus.
The contribution of stromal genes signatures to drug sensi-
tivity clearly emerges in a correlative study with a high level of
evidence since carried out in the context of the EORTC 10994 neoad-
juvant trial of chemotherapy on patients with ER-negative tumors
[56], Gene expression proﬁles obtained on pre-treatment biopsies
allowed the identiﬁcation of a stroma metagene, composed by the
expression average of 50 genes, with a prominent exhibition of ECM
proteins, whose high expression was  associated with resistance
to 5-ﬂuorouracil, epirubicin, and cyclophosphamide (FEC) treat-
ment (Table 1). This metagene includes genes encoding for different
chains of collagene (COL1A2, COL10A1, COL3A1, COL6A3, COL6A1,
COL10A1), metalloproteases (MMP2, MMP11, MMP14) and other
genes involved in the regulation of ECM (SPARC, LOXL1, FBLN1,
ADAM12, ECM2). This same stromal metagene proved to be asso-
ciated with resistance to chemotherapy even in an independent
cohort of ER-negative tumors, included in a study of neoadju-
vant chemotherapy with paclitaxel, 5-ﬂuorouracil, doxorubicin and
ciclophosphamide [57], at the MD  Anderson Medical Center.
The dynamic change of ECM, in addition to have a predictive role
on tumor progression, also demonstrated to be relevant in medi-
ating resistance to chemo-, hormone and radio-treatment through
different mechanisms [58], including low vascular density, which
causes an insufﬁcient blood ﬂow determining a poor drug delivery
[59], the expression of matricellular proteins SPP1 and THBS1 able
to induce resistance to apoptosis mediated by cyclophosphamide
and doxorubicin, respectively [60,61], the increase of collagene I
that in response to drugs [62] induces ECM to become stiffer and
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hereby further reduces the ability of the drugs to penetrate the
umor.
Weigelt and colleagues showed that the sensitivity to
rastuzumab, pertuzumab and lapatinib of non-resistant HER2+
ells grown on laminin-rich ECM in 3D cultures, could be increase
y adding anti-integrin 1 antibody [63]. The explanation of this
ata is that the major ECM proteins ﬁbronectin, collagen and
aminin are ligands for integrins, and this binding changes pro-
oundly the behavior of tumor cells, through the activation of
ifferent molecular pathways, which lead the drug resistance [64],
hrough a mechanism called “cell adhesion-mediated drug resis-
ant”.
Much efforts are needed to clearly deﬁne function and compo-
ition of different stroma components, in order to deﬁne predictive
ignatures for speciﬁc treatments and to design new targeted ther-
pies.
. ECM stiffness in tumor progression and resistance to
herapy
It is generally recognized that breast cancer is characterized
y increasing stiffness of tissue, helping to detect disease by pal-
ation or elastography [65]. Indeed, it is well-documented that
he healthy mammary gland is highly compliant, while the aver-
ge tumor is more than one order of magnitude stiffer [66,67].
pithelial cancers are characterized by an altered tissue ten-
ion homeostasis that reﬂects increased cell-generated force in
he transformed cells, increased compression force due to the
olid state pressure exerted by the expanding tumor mass, and
atrix stiffening due to the desmoplastic response [68,69]. ECM
hanges dynamically in composition and orientation [70], induc-
ng mechanical perturbations that may  also have a causal role in
umor progression [71]. Provenzano et al. [72], using an in vivo
odel of bi-transgenic mice, provided the ﬁrst evidence of a
ausal link between increased stroma collagen deposition and
nhanced tumorigenesis, local invasion and metastases due to this
ugmented density. Since then, the role of stiffness in driving
umor progression has been widely studied. Using the MMTV-Neu
ransgenic mouse model, Levental et al. [73] demonstrated that
reast cancer development is accompanied by progressive colla-
en deposition and crosslinking, LOX expression and increased
CM stiffness, with consequent enhanced focal adhesion and PI3K
ctivity in tumor cells. Consistent with these ﬁndings, increased
atrix stiffness was found to enhance adhesion signals and a
hronic activation of the FAK-Rho-ERK network [74]. More recently,
ouw et al. [75] demonstrated microRNA involvement in integrin-
ependent cell-matrix interaction. Speciﬁcally, their ﬁndings in
n vivo models identiﬁed miR-18a as a mechanically regulated
umor enhancer that represses PTEN and promotes PI3K, inducing
umor progression after FAK- and B-catenin-mediated induction. In
uman breast carcinoma samples, the authors found a positive cor-
elation between miR-18a expression levels and tumor increased
tiffness, and an inverse correlation between miR-18a expression
nd time to distant relapse-free survival regardless of tumor molec-
lar subtypes. Very recently, Wei  et al. [76] showed that increasing
atrix stiffness activates epithelial–mesenchimal transition (EMT)
nd tumor invasion through the EMT-inducing transcription factor
WIST1. Mechanistically, their study revealed that stiffness induces
he release of TWIST1 from its anchor G3BP2 to enter the nucleus
nd trascriptionally promotes EMT  through clustering and activa-
ion of integrins. Notably, patients whose breast cancers showed
rganized collagen (evaluated by second armonic generation imag-
ng and considered as a surrogate marker for matrix rigidity), and
educed G3BP2 had a markedly unfavorable outcome compared
o disorganized/G3BP2-high cases. Overall, current data indicatecer Biology 35 (2015) 3–10
that a variety of molecular characteristics of ECM lead to different
mechanical properties of stiffness which, in turn, can differentially
affect breast cancer progression.
As regards the impact of ECM composition on response to ther-
apy, matrix stiffness has also been documented as an important
parameter in drug resistance. In vitro studies [77,78] have demon-
strated the low response to chemotherapeutic agents by different
cancer cell lines, including breast, when cultured on stiff substrates.
In this context, JNK was found to be a key mediator of sorafenib
resistance [77]. Consistent with these preclinical data, Hayashi
et al. [79] demonstrated the potential value of tumor stiffness, as
evaluated by elastography, in predicting response to neoadjuvant
chemotherapy; indeed, patients with soft breast carcinomas were
highly responsive to therapy and more frequently displayed patho-
logical complete response than did patients with stiff tumors. Such
a relationship was also conﬁrmed using shear-wave elastography
to measure stiffness [80].
In addition, a study performed on in vivo xenograft mouse mod-
els indicated that albumin and immunoglobulins diffusion within
tumor was  impaired by tumor rigidity [81], suggesting that efﬁ-
cacy of therapies with biological drugs as monoclonal antibodies
may  be profoundly affected by tissue architecture and rigidity. A
possible explanation may  be that mechanical forces generated by
stiffed microenvironment impair perfusion due to vessel compres-
sion decreasing drug delivery and efﬁcacy as clearly demonstrated
in pancreatic cancer models [82,83].
It is worthy of note that tumor stiffness decreases when patients
respond to therapy, indicating the importance of using ultrasound
elastography as a measure of tumor stiffness to monitor neoadju-
vant treatment response in locally advanced breast cancer patients
[84].
While current data clearly identify ECM stiffness as an impor-
tant parameter to consider when studying the ECM role in breast
carcinomas, the variety of ECM signatures with prognostic and pre-
dictive signiﬁcance and the different effects of mechanical cues
depending on ECM components and consequent cognate receptors
engaged by tumor cells [85] call for further studies to elucidate
the relationship between ECM composition and mechanical cues
before translating knowledge of tumor microenviromental signals
to clinical practice.
6. Conclusions
An aggressive phenotype could be the result of an efﬁcient
interaction between in situ or invasive lesions and the surround-
ing stroma in two  possible ways: (i) stromal changes in the organ
might create an environment permissive for cancer growth and/or
(ii) early (pre)neoplastic lesions might establish a productive cross-
talk with the surrounding stroma in a process even mediated by
ECM components and dependent on the genetic alterations of
the epithelial cells and on the microenvironmental responses of
the host (also possibly dependent on constitutive genetic varia-
tions). In both scenarios the study of stromal and ECM alterations
is instrumental for providing novel information to change our
understanding of the aggressive and lethal form of cancer. Pre-
dicted outcomes could be (i) the identiﬁcation of individuals at
risk of developing aggressive disease from signatures of circulat-
ing biomarkers of stromal origin and (ii) the deﬁnition of stromal
changes indicative of high risk of invasive evolution or recurrence
for individual neoplastic lesions.
Transcriptional and even microRNA signatures of target tissues
may represent a clue of early changes in stromal microenvironment
that could be related to the predisposition to develop malignant
lesions characterized by distinct clinical behaviors. Nevertheless,
in breast cancer gene expression proﬁles of tumor ﬁbroblasts iden-
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ify distinct stroma patterns indicative of clinical outcome, and
he expression proﬁle of some extracellular matrix genes pro-
ide clinically relevant information to identify patients at high
isk to progress and/or to become resistant to chemical and phys-
cal agents. However, all these ﬁndings, although promising and
elatively robust if considering the overlapping of ECM-related can-
idate genes across the different signatures, need to be validated
nd corroborated by further structural and functional studies to
eﬁne function and composition of the distinct stroma compo-
ents, and integrated by proteomic studies to compose and clarify
he complex frame of interactions between tumor cells and their
urrounding microenvironment.
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